AbCellera Biologics Inc. Revenue
AbCellera Biologics Inc. (ABCL) reported Revenue of $4.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.05M, a 76.29% decline year-over-year.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $8.31M, a 96.34% increase year-over-year.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $44.85M, a 788.18% increase year-over-year.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $8.96M, a 37.62% increase year-over-year.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $75.13M, a 160.56% increase from fiscal 2024.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $28.83M, a 24.17% decline from fiscal 2023.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $38.02M, a 92.17% decline from fiscal 2022.
- AbCellera Biologics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $485.42M, a 29.38% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.05M 10-Q · filed 2026-08-05 | $12.36M 10-Q · filed 2026-08-05 | $57.22M derived: sum of 3 quarters · filed 2026-08-05 | $66.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $8.31M 10-Q · filed 2026-05-11 | $53.17M derived: sum of 2 quarters · filed 2026-05-11 | $62.12M derived: sum of 3 quarters · filed 2026-05-11 | $79.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $44.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $53.81M derived: sum of 2 quarters · filed 2026-02-24 | $70.89M derived: sum of 3 quarters · filed 2026-08-05 | $75.13M 10-K · filed 2026-02-24 |
| 2025-09-30 | $8.96M 10-Q · filed 2025-11-06 | $26.04M derived: sum of 2 quarters · filed 2026-08-05 | $30.27M 10-Q · filed 2025-11-06 | $35.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $17.08M 10-Q · filed 2026-08-05 | $21.32M 10-Q · filed 2026-08-05 | $26.37M derived: sum of 3 quarters · filed 2026-08-05 | $32.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.24M 10-Q · filed 2026-05-11 | $9.29M derived: sum of 2 quarters · filed 2026-05-11 | $15.79M derived: sum of 3 quarters · filed 2026-05-11 | $23.11M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.56M derived: sum of 2 quarters · filed 2026-02-24 | $18.88M derived: sum of 3 quarters · filed 2026-02-24 | $28.83M 10-K · filed 2026-02-24 |
| 2024-09-30 | $6.51M 10-Q · filed 2025-11-06 | $13.83M derived: sum of 2 quarters · filed 2025-11-06 | $23.78M 10-Q · filed 2025-11-06 | $32.96M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $7.32M 10-Q · filed 2025-08-07 | $17.28M 10-Q · filed 2025-08-07 | $26.46M derived: sum of 3 quarters · filed 2026-02-24 | $33.05M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $9.95M 10-Q · filed 2025-05-08 | $19.13M derived: sum of 2 quarters · filed 2026-02-24 | $25.73M derived: sum of 3 quarters · filed 2026-02-24 | $35.79M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.78M derived: sum of 2 quarters · filed 2026-02-24 | $25.83M derived: sum of 3 quarters · filed 2026-02-24 | $38.02M 10-K · filed 2026-02-24 |
| 2023-09-30 | $6.60M 10-Q · filed 2024-11-04 | $16.66M derived: sum of 2 quarters · filed 2024-11-04 | $28.85M 10-Q · filed 2024-11-04 | $50.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $10.06M 10-Q · filed 2024-08-06 | $22.25M 10-Q · filed 2024-08-06 | $43.79M derived: sum of 3 quarters · filed 2025-02-27 | $145.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $12.19M 10-Q · filed 2024-05-07 | $33.74M derived: sum of 2 quarters · filed 2025-02-27 | $135.12M derived: sum of 3 quarters · filed 2025-02-27 | $181.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $21.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $122.93M derived: sum of 2 quarters · filed 2025-02-27 | $168.84M derived: sum of 3 quarters · filed 2025-02-27 | $485.42M 10-K · filed 2025-02-27 |
| 2022-09-30 | $101.38M 10-Q · filed 2023-11-02 | $147.30M derived: sum of 2 quarters · filed 2023-11-02 | $463.88M 10-Q · filed 2023-11-02 | $603.21M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $45.92M 10-Q · filed 2023-08-03 | $362.50M 10-Q · filed 2023-08-03 | $501.83M derived: sum of 3 quarters · filed 2024-02-20 | $507.34M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $316.58M 10-Q · filed 2023-05-04 | $455.91M derived: sum of 2 quarters · filed 2024-02-20 | $461.42M derived: sum of 3 quarters · filed 2024-02-20 | $489.06M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $139.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $144.84M derived: sum of 2 quarters · filed 2024-02-20 | $172.48M derived: sum of 3 quarters · filed 2024-02-20 | $375.20M 10-K · filed 2024-02-20 |
| 2021-09-30 | $5.51M 10-Q · filed 2022-11-08 | $33.15M derived: sum of 2 quarters · filed 2022-11-08 | $235.87M 10-Q · filed 2022-11-08 | $443.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $27.64M 10-Q · filed 2022-08-09 | $230.38M 10-Q · filed 2022-08-09 | $438.29M derived: sum of 3 quarters · filed 2023-02-21 | $447.65M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $202.74M 10-Q · filed 2022-05-10 | $410.65M derived: sum of 2 quarters · filed 2023-02-21 | $420.01M derived: sum of 3 quarters · filed 2023-02-21 | $431.24M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $207.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $217.27M derived: sum of 2 quarters · filed 2023-02-21 | $228.50M derived: sum of 3 quarters · filed 2023-02-21 | $233.16M 10-K · filed 2023-02-21 |
| 2020-09-30 | $9.36M 10-Q · filed 2021-11-10 | $20.59M derived: sum of 2 quarters · filed 2021-11-10 | $25.25M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $11.23M 10-Q · filed 2021-08-13 | $15.88M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $4.66M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $11.61M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |